Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Defective delivery system.
Consumers and healthcare providers should stop using this product immediately. Contact Meitheal Pharmaceuticals, Inc or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The affected product is Diclofenac Sodium, Topical Gel, 3% in 100 g tubes. It was manufactured by Taro Pharmaceuticals Inc. in Brampton, Ontario, Canada. Lot numbers include AD92720, AD92722, and AD92723, with an expiration date of March 31, 2027.
The viscosity of Diclofenac Sodium Gel, 3% does not meet specifications. This could affect the efficacy of the medication, posing a risk to users.
No specific incidents or injuries have been reported related to this withdrawal. The company has initiated this action purely as a precaution.
Stop using the product immediately. Contact Sun Pharmaceutical Industries Inc. or your healthcare provider for further guidance on this issue.
For questions, consumers can reach Sun Pharmaceutical Industries at their official website or contact their healthcare provider for more information.
Get instant alerts for recalls that affect you. Free forever.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Asteria Health recalled 670 testosterone pellets on January 26, 2026, due to potential metal particulate contamination. Consumers and healthcare providers must stop using the product immediately. The recall affects all units distributed nationwide in the United States.